Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Comment on: Have we reached the limits for the treatment of diabetic nephropathy?
Onuigbo, Macaulay AC, Onuigbo, Macaulay A C

Expert Opinion on Investigational Drugs | May 6, 2014 | Volume: 23 | Issue: 6 | Pages: 883-884

10.1517/13543784.2014.912376 | PMID 24797242 Get It

Laying to Rest Psychostimulants for Cancer-Related Fatigue?
Ruddy, Kathryn J. , Barton, Debra L. , Loprinzi, Charles L.

Journal of Clinical Oncology | May 6, 2014 | Volume: 32 | Issue: 18 | Pages: 1865-1867

10.1200/jco.2014.55.8353 | PMID 24799492 Get It

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
Ramakrishna, Naren , Temin, Sarah , Chandarlapaty, Sarat , Crews, Jennie R. , Davidson, Nancy E. , Esteva, Francisco J. , Giordano, Sharon H. , González-Angulo, Ana M. , Kirshner, Jeffrey J., Krop, Ian E. , Levinson, Jennifer, Modi, Shanu , Patt, Debra A. , Perez, Edith A. , Perlmutter, Jane , Krop, Ian, Winer, Eric P. , Lin, Nancy U. , Modi, Shanu

Journal of Clinical Oncology | May 6, 2014 | Volume: 32 | Issue: 19 | Pages: 2100-2108

10.1200/jco.2013.54.0955 | PMID 24799487 Get It

Purpose To provide formal expert consensus–based recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2) –positive advanced breast cancer. Methods The American Society of Clinical Oncology (ASCO) convened a panel of medical oncology, radiation oncology, guideline implementation, and advocacy experts and conducted a systematic review of the literature. When that failed to yield sufficiently strong quality evidence, the Expert Panel undertook a formal expert consensus–based process to produce these recommendations. ASCO used a modified Delphi process. The panel members drafted recommendations, and a group of other experts joined them for two rounds of formal ratings of the recommendations. Results No studies or existing guidelines met the systematic review criteria; therefore, ASCO conducted a formal expert consensus–based process. Recommendations Patients with brain metastases should receive appropriate local therapy and systemic therapy, if indicated. Local therapies include surgery, whole-brain radiotherapy, and stereotactic radiosurgery. Treatments depend on factors such as patient prognosis, presence of symptoms, resectability, number and size of metastases, prior therapy, and whether metastases are diffuse. Other options include systemic therapy, best supportive care, enrollment onto a clinical trial, and/or palliative care. Clinicians should not perform routine magnetic resonance imaging (MRI) to screen for brain metastases, but rather should have a low threshold for MRI of the brain because of the high incidence of brain metastases among patients with HER2-positive advanced breast cancer.
Role of Rehabilitation Medicine and Physical Agents in the Treatment of Cancer-Associated Pain
Basford, Jeffrey R. , Cheville, Andrea

Journal of Clinical Oncology | May 6, 2014 | Volume: 32 | Issue: 16 | Pages: 1691-1702

10.1200/jco.2013.53.6680 | PMID 24799472 Get It

Purpose To provide an overview of rehabilitation medicine– and physical modality–based approaches to cancer pain management, and to highlight the fact that these approaches are generally used in conjunction and that a majority are focused on minimizing pain during periods of mobility and the performance of activities of daily living. Methods We performed a nonsystematic literature review and provide a description of the current standard of care. Results Rehabilitative and physical modalities used to manage pain can be grouped into four categories: those that modulate nociception, stabilize or unload painful structures, influence physiological processes that indirectly influence nociception, or alleviate pain arising from the overloading of muscles and connective tissues that often occurs after surgery or with sarcopenia in late-stage cancer. Most modalities have been pragmatically refined over the years, and many have an evidence base, although few have been explicitly validated in the oncologic setting. With few exceptions, they are patient controlled and free of adverse effects. Conclusion Physical modalities and rehabilitation medicine offer a range of pain management approaches that may serve as beneficial adjuncts to the conventional systemic and interventional analgesic strategies used to control cancer-related pain. These approaches may be particularly beneficial to patients with movement-associated pain and those who are ambivalent regarding pharmacoanalgesia.
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Pflug, Natali , Bahlo, Jasmin, Eichhorst, Barbara , Bergmann, Manuela A., Elter, Thomas , Bauer, K. H. , Malchau, Gebhart, Rabe, Kari G. , Jäger, Ulrich, Eckart, Michael J., Busch, Raymonde, Fink, Anna‐Maria , Wendtner, Clemens‐Martin , Fischer, Kirsten , Hallek, Michael , Shanafelt, Tait D. , Stilgenbauer, Stephan , Döhner, Hartmut , Hopfinger, Georg , Kay, Neil E. , Chaffee, Kari G.

Blood | May 6, 2014 | Volume: 124 | Issue: 1 | Pages: 49-62

10.1182/blood-2014-02-556399 | PMID 24797299 Get It

Key PointsPrognostic tool for CLL patients with high discriminatory power compared with conventional clinical staging systems. Prognostication on the individual patient level independent of clinical stage.
Quantification of Serum IgG Subclasses by Use of Subclass-Specific Tryptic Peptides and Liquid Chromatography–Tandem Mass Spectrometry
Ladwig, Paula M. , Barnidge, David R. , Snyder, Melissa R. , Katzmann, Jerry A., Murray, David , Murray, David L.

Clinical Chemistry | May 6, 2014 | Volume: 60 | Issue: 8 | Pages: 1080-1088

10.1373/clinchem.2014.222208 | PMID 24799527 Get It

AbstractBACKGROUNDMeasurement of IgG subclasses is a useful tool for investigation of humoral immune deficiency in the presence of total IgG within reference intervals and IgG4-related disease. Nephelometry has been the method of choice for quantification. We describe an LC-MS/MS method that can multiplex all 4 subclasses along with total IgG by use of either IgG subclass-specific peptide stable isotope–labeled internal standards or a surrogate digest standard for quantification and does not rely on antigen/antibody reactions.METHODSWe combined serum with labeled internal peptide standards and intact purified horse IgG. Samples were denatured, reduced, alkylated, and digested. We analyzed the digested serum by LC-MS/MS for IgG subclasses 1–4 and total IgG.RESULTSWe assayed 112 patient sera by LC-MS/MS and immunonephelometry. The mean of the slopes and R2 values for IgG1, IgG2, IgG3, IgG4, and IgG were 1.18 and 0.93, respectively. Interassay imprecision for the LC-MS/MS method was <15% for total IgG and subclasses and was slightly improved by use of a calibrator peptide from an exogenous horse IgG. Summed total IgG correlated with the measured total IgG within 10%. Reference intervals and analytical measuring range were all similar to our previous validation data for the immunonephelometry assays.CONCLUSIONSTotal IgG and IgG subclasses 1, 2, 3, and 4 can be quantified by LC-MS/MS with performance comparable to nephelometry.
Costs of Allogeneic Hematopoietic Cell Transplantation Using Reduced Intensity Conditioning Regimens
Khera, Nandita , Emmert, Amy, Storer, Barry E. , Alyea, Edwin P. , Lee, Stephanie J. , Sandmaier, Brenda M, Sandmaier, Brenda M , Lee, Stephanie J

The Oncologist | May 6, 2014 | Volume: 19 | Issue: 6 | Pages: 639-644

10.1634/theoncologist.2013-0406 | PMID 24797822 Get It

Abstract Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs between 100 days and 2 years after HCT were available for one cohort (n = 311); median costs during this period were $39,000 and accounted for 39% of costs during the first 2 years. Late costs were not associated with any pretransplant variables, but were higher with extensive chronic GVHD and death. After adjustment for clinical characteristics, the overall costs of the RIC transplants were similar between the two institutions despite different management approaches (inpatient vs. outpatient conditioning) and accounting methodologies. Use of unrelated/alternative donors, transplant for diseases other than lymphoma or myeloma, and acute GVHD were predictors for higher early costs, and extensive chronic GVHD and death were associated with higher late costs.
Pathology of Renal Diseases Associated with Dysfunction of the Alternative Pathway of Complement: C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome (aHUS)
Sethi, Sanjeev , Fervenza, Fernando C.

Seminars in Thrombosis and Hemostasis | May 6, 2014 | Volume: 40 | Issue: 04 | Pages: 416-421

10.1055/s-0034-1375701 | PMID 24799306 Get It

Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature
Downing, Nicholas S., Cheng, Theresa M., Shah, Nilay D. , Ross, Joseph S. , Cheng, Theresa, Krumholz, Harlan M. , Ross, Joseph S

JAMA Internal Medicine | May 6, 2014 | Volume: 174 | Issue: 7 | Pages: 1176

10.1001/jamainternmed.2014.1371 | PMID 24796406 Get It

Telomere Length Varies by DNA Extraction Method: Implications for Epidemiologic Research—Response
Boardman, Lisa A., Skinner, Halcyon G. , Litzelman, Kristin , Boardman, Lisa A.

Cancer Epidemiology, Biomarkers & Prevention | May 5, 2014 | Volume: 23 | Issue: 6 | Pages: 1131-1131

10.1158/1055-9965.epi-14-0234 | PMID 24798728 Get It